Infection in vitro, this protein was tested for clinical efficacy in HIV-1-infected individuals; however, no effect on plasma viral loads was observed [13]. Further examination revealed that doses of sCD4 that were significantly higher than those achieved in the clinical trial were required to neutralize primary clinical isolates of HIV-1, in contrast to the relatively sensitive, laboratory-adapte
Effects of inflammation on health during chronic HIV infection. Immunity 2013; 39: 633?45. 55. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203. 56. Neuhaus J, Jacobs Jr DR, Baker JV, Calmy A, Duprez D, La Rosa A et al. Markers of inflammation, coagulation, and renal func
Effects of inflammation on health during chronic HIV infection. Immunity 2013; 39: 633?45. 55. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203. 56. Neuhaus J, Jacobs Jr DR, Baker JV, Calmy A, Duprez D, La Rosa A et al. Markers of inflammation, coagulation, and renal func
Ied [31,32]. These compounds, which include the prototypic compound NBD556 and its derivatives, mimic the effects of CD4 by inducing the exposure of the coreceptor-binding site on gp120 [31,33]. Although NBD-556 inhibits HIV-1 infection of CD4+CCR5+ cells, it can replace CD4 and thus enhance HIV-1 infection of CD42CCR5+ cells [31]. In view of their capacity to enhance infectivity, any potential ap
Effects of inflammation on health during chronic HIV infection. Immunity 2013; 39: 633?45. 55. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203. 56. Neuhaus J, Jacobs Jr DR, Baker JV, Calmy A, Duprez D, La Rosa A et al. Markers of inflammation, coagulation, and renal func